BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CeraPedics L.L.C. To Discuss Proprietary Synthetic Bone Graft Product At Medtech Insight "In Spine" Conference


10/25/2005 2:00:19 PM

LAKEWOOD, Colo., Oct. 25 /PRNewswire/ -- Andrew Tofe, PhD, President and CEO of CeraPedics, will make a presentation at Medtech Insight's "In Spine & Orthopedics" conference on November 2 at 9:30 a.m. at the Westin Stonebriar Resort in North Dallas, Texas. Dr. Tofe will discuss the development of P-15 Putty, which is an orthopedic bone graft material consisting of the synthetic P-15 peptide bound to anorganic bone mineral (ABM) suspended in an inert hydrogel carrier.

According to Dr. Tofe, "P-15 differs from existing commercially available growth factors in that it does not convert undifferentiated cells into bone cells. Instead, it initiates a chain of cellular changes that kick starts the production of new bone. These characteristics make P-15 not only very effective in promoting new bone growth but also very safe."

CeraPedics is a privately held company focused on the development of synthetic bone graft products incorporating its proprietary P-15 technology. In September, CeraPedics filed for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to conduct a clinical investigation to study the safety and efficacy of P-15 Putty when used for spine fusion. P-15 was previously approved by the FDA in 1999 for use in dental bone growth applications.

According to Medtech Insight's web site, the "In Spine & Orthopedics" conference "will provide a focused, single-track forum for our large group of emerging, privately held spine and orthopedic companies to present to an audience of venture capitalists, investment bankers, corporate business development executives, and clinicians for purposes of funding, acquisition, and/or strategic partnership."

CeraPedics, L.L.C.

CONTACT: Don Freeman, Business Development Manager of CeraPedics, L.L.C.,+1-303-980-1781, dfreeman@cerapedics.com; or Matt Swetonic of TheDilenschneider Group, +1-212-922-0900, mswetonic@dgi-nyc.com, forCeraPedics, L.L.C.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES